Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Greater China.
Frontage is pleased to announce the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc. and President of Frontage Greater China. Dr. Qi has nearly 30 years of experience in research and development leadership and overseeing operations in the regulated pharmaceutical industry. In this role, Dr. Qi will be responsible for the overall leadership and strategic growth of Frontage Greater China operations.
“I am very excited to welcome Dr. Yining Qi onboard as our Executive Vice President, Frontage Laboratories and President of Frontage Greater China Region”, said Dr. Song Li, CEO of Frontage Laboratories. “Dr. Qi’s extensive experiences in both pharmaceutical companies and CRO businesses make him ideally suited to lead Frontage Greater China District’s operations. We have confidence in his leadership to grow Frontage’s business.”
Before joining Frontage, Dr Qi served as Vice President of R&D, RA and Medical and President of research institute for Hebei Changshan Biochemical Pharmaceutical Company Inc. Prior to that, he was global Senior VP of Operation & General Manager (Taicang) of Crown Bioscience Inc. and served as Board Chairman and General Manager of Taicang-Crownbio Biopharmaceutical Analysis, Inc. Dr. Qi has held several other notable roles including: Executive Director of Technical Operation, Client Services and Project Management of WuXi AppTec (Suzhou) Co., Ltd.; Research Fellow, Group Leader, Laboratory Technical Operations (LTO) Safety Assessment of Merck Research Laboratories (MRL); Sr. Clinical Project Manager/DBA of Becton, Dickinson and Company; Director of Department of Toxicology and Pharmacology, Beijing Institute for Drug Control of NMPA Beijing Branch.
Dr. Qi received a Master of Business Administration in Pharmaceutical Management from Rutgers University in 2007, a Master of Science in Computer Science from Southeastern University in 1999, a Master of Public Health from Shanxi Medical University in 1991, and a Bachelor of Medicine (M.D. equivalent) from Shanxi Medical University in 1984.
“It’s my great honor and pleasure to join Frontage,” said Dr. Qi. “I believe that my past R&D and management experience will further help to enhance Frontage’s ability to provide high quality and efficient service for pharmaceutical companies and R&D institutions.”